“The Applicant evaluated the safety of adagrasib in GLP-compliant 28-day and 13-week repeat-dose toxicology studies in Sprague-Dawley rats and Beagle dogs, using the intended oral route of administration.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Why that species
Selected based on in vitro and in vivo metabolism studies
“The rat and dog were selected as preclinical species for toxicology studies based on results from in vitro and in vivo metabolism studies, which is supported.”
“The Applicant evaluated the safety of adagrasib in GLP-compliant 28-day and 13-week repeat-dose toxicology studies in Sprague-Dawley rats and Beagle dogs, using the intended oral route of administration.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Species: general tox
Sprague-Dawley rat and beagle dog (28-day and 13-week)
“The Applicant evaluated the safety of adagrasib in GLP-compliant 28-day and 13-week repeat-dose toxicology studies in Sprague-Dawley rats and Beagle dogs, using the intended oral route of administration.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Species: DART
Rat and rabbit (EFD only); no fertility or pre/postnatal studies (ICH S9)
“DRF and definitive EFD studies were performed in Wistar rat and NZW rabbits. No fertility, early embryonic development or PPND studies were performed.”
“Dedicated carcinogenicity studies were not conducted with adagrasib, as they are not needed to support the use of a drug intended to treat patients with advanced cancer.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Surrogate used in
No surrogate used; rat and dog selected on metabolism data
“The rat and dog were selected as preclinical species for toxicology studies based on results from in vitro and in vivo metabolism studies, which is supported.”